JPRN-jRCT2080222789未知1 期
Phase 1b study of Process 2 Patritumab in combination with erlotinib in subjects with advanced non-small cell lung cancer (NSCLC)
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 18 人开始时间: 2015年3月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Histologically or cytologically diagnosed advanced NSCLC has progressed on at least one prior chemotherapy
- •2) Stage IIIB or IV disease
- •3) ECOG performance status: 0-1
排除标准
- •1) Has history of anti-HER3 therapy
- •2) Patients with active other malignancies
- •3) Has history or complication of any of the following diseases: interstitial lung disease, heart failure, myocardial infarction, cerebral infarction, active angina, arrhythmia requiring medication, coronary/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thrombosis, deep vein thrombosis, other clinically significant thromboembolic events, diverticulitis, or clinically significant pulmonary disease (e.g., lung infection, COPD, or asthma)
- •4) Patients with any severe or uncontrolled comorbid medical conditions in spite of medications
- •5) Has brain metastasis with clinical symptoms or requiring treatment
- •6) Has history of bleeding diathesis (e.g., hemoptysis)
- •7) Has history of serious drug hypersensitivity such as anaphylactoid reaction
研究者
相似试验
尚未招募
Unknown
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusioKCT0009451Samsung Medical Center30
进行中（未招募）
不适用
A Phase II Clinical Trial of Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine (XELOX) Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases - NDPreviously untreated Patients with Colorectal Cancer and Advanced Liver Metastases.MedDRA version: 9.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-002007-41-ITAZIENDA OSPEDALIERA ORDINE MAURIZIANO
已完成
2 期
Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000011440onprofit Organization Japan Clinical Cancer Research Organization35
进行中（未招募）
不适用
An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer.Ensayo Clínico fase II de Panitumumab combinado con quimioterapia de Irinotecan como tratamiento de segunda linea en sujetos con cáncer colorectal metastásico.EUCTR2006-006363-24-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)80
招募中
2 期
Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy2023-505923-30-00Institut Gustave Roussy99